Greenline Partners’s Haemonetics HAE Stock Holding History

Greenline Partners’s Portfolio HAE Stock Details HAE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q2	–	Sell	-3	Closed	-$191	–	328
2025 Q1	$191	Buy	+3	New	+$204	﹤0.01%	537

Other funds holding HAE

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Neuberger Berman Group New York $131B AUM 28.36% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

RRAM

River Road Asset Management Louisville, Kentucky $8.99B AUM 12.83% 1-Year Est. Return

T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return

Royce & Associates New York $10.1B AUM 42.88% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return

Greenline Partners's HAE Position: Q2 2025 in Review

Greenline Partners sold out of Haemonetics (HAE) in Q2 2025, closing a stake of 3 shares — an estimated $191 sold.

Greenline Partners first reported a position in HAE in Q1 2025 and held it in 1 quarter. The position peaked at $191 in Q1 2025. 298 funds tracked by Wall St. Rank hold HAE as of Q2 2025.

Greenline Partners reported no remaining Haemonetics position as of Q2 2025 after selling out during the quarter.
Greenline Partners sold 3 Haemonetics shares in Q2 2025, an estimated $191.
Greenline Partners first reported a position in Haemonetics in Q1 2025 and held it in 1 quarter.
Greenline Partners's Haemonetics position peaked at $191 in Q1 2025.
298 funds tracked by Wall St. Rank held Haemonetics as of Q2 2025.

Based on Greenline Partners's 13F filing for Q2 2025, filed 14 Aug 2025.